clinical trial · NCT06984094
First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Clover Biopharmaceuticals AUS Pty·phase1·recruiting·n = 192
Respiratory Syncytial Virus VaccinationHuman Metapneumovirus VaccinationParainfluenza VaccinationSCB-1019TSCB-1022SCB-1033
brief summary
This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.
started
Jun 18, 2025
primary completion
Mar 3, 2026
completion
Jun 30, 2026
last updated
Aug 8, 2025
detailed description
The study will descriptively evaluate three dose levels of SCB-1022 and SCB-1033. The sample size for this study is not based on formal statistical hypothesis testing but is acceptable for safety and immunogenicity evaluation in a phase 1 study. The study will be overseen by a safety monitoring committee.
official title
A Phase 1, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1022 and SCB-1033 in Healthy Older Adults Aged 60-85 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol